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Summary
Background Mortality rates in hospitalised patients with COVID-19 in the UK appeared to decline during the first 
wave of the pandemic. We aimed to quantify potential drivers of this change and identify groups of patients who 
remain at high risk of dying in hospital.
Methods In this multicentre prospective observational cohort study, the International Severe Acute Respiratory and 
Emerging Infections Consortium WHO Clinical Characterisation Protocol UK recruited a prospective cohort of 
patients with COVID-19 admitted to 247 acute hospitals in England, Scotland, and Wales during the first wave of the 
pandemic (between March 9 and Aug 2, 2020). We included all patients aged 18 years and older with clinical signs and 
symptoms of COVID-19 or confirmed COVID-19 (by RT-PCR test) from assumed community-acquired infection. We 
did a three-way decomposition mediation analysis using natural effects models to explore associations between week 
of admission and in-hospital mortality, adjusting for confounders (demographics, comorbidities, and severity of 
illness) and quantifying potential mediators (level of respiratory support and steroid treatment). The primary outcome 
was weekly in-hospital mortality at 28 days, defined as the proportion of patients who had died within 28 days of 
admission of all patients admitted in the observed week, and it was assessed in all patients with an outcome. This 
study is registered with the ISRCTN Registry, ISRCTN66726260.
Findings Between March 9, and Aug 2, 2020, we recruited 80 713 patients, of whom 63 972 were eligible and included in 
the study. Unadjusted weekly in-hospital mortality declined from 32·3% (95% CI 31·8–32·7) in March 9 to April 26, 2020, 
to 16·4% (15·0–17·8) in June 15 to Aug 2, 2020. Reductions in mortality were observed in all age groups, in all ethnic 
groups, for both sexes, and in patients with and without comorbidities. After adjustment, there was a 32% reduction in 
the risk of mortality per 7-week period (odds ratio [OR] 0·68 [95% CI 0·65–0·71]). The higher proportions of patients 
with severe disease and comorbidities earlier in the first wave (March and April) than in June and July accounted for 
10·2% of this reduction. The use of respiratory support changed during the first wave, with gradually increased use of 
non-invasive ventilation over the first wave. Changes in respiratory support and use of steroids accounted for 22·2%, OR 
0·95 (0·94–0·95) of the reduction in in-hospital mortality.
Interpretation The reduction in in-hospital mortality in patients with COVID-19 during the first wave in the UK was 
partly accounted for by changes in the case-mix and illness severity. A significant reduction in in-hospital mortality 
was associated with differences in respiratory support and critical care use, which could partly reflect accrual of 
clinical knowledge. The remaining improvement in in-hospital mortality is not explained by these factors, and could 
be associated with changes in community behaviour, inoculum dose, and hospital capacity strain.
Funding National Institute for Health Research and the Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
There is growing evidence that mortality from COVID-19 
declined during the first wave of the pandemic in the UK, 
both in hospital and in the community.1–5 One explanation 
for this decline could be that the case-mix of patients 
presenting to hospital changed across time towards a 
younger and less comorbid demographic, who were at 
lower risk of dying than were patients at the start of the 
first wave. The national UK lockdown and effective 
shielding measures in susceptible at-risk populations 
could have reduced transmission of the virus during the 
course of the first wave.6 Additionally, easier access to 
testing and advice about seeking medical help might have 
resulted in earlier presentation to hospital. Familiarity 
with the virus and clinical course could have also led to 
better management of patients through improved ward 
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and intensive care unit (ICU) care.7,8 Corticosteroids have 
been shown in trials to reduce mortality in patients with 
severe COVID-19, and there was an increase in the use of 
corticosteroids during the course of the first wave.9,10
The International Severe Acute Respiratory and 
Emerging Infections Consortium (ISARIC) WHO 
Clinical Characterisation Protocol UK (CCP-UK)11 was 
activated on Jan 17, 2020, to recruit patients with 
COVID-19 admitted to a network of hospitals in England, 
Scotland, and Wales.12 ISARIC has been prepared for 
outbreaks such as COVID-19 for the past 8 years, with the 
aim of providing data and samples for near real-time 
analysis.11 During the COVID-19 outbreak, analysis of the 
CCP-UK cohort in the first wave allowed development of 
the pragmatic International Severe Acute Respiratory and 
Emerging Infections Consortium Coronavirus Clinical 
Characterisation Consortium (ISARIC4C) Mortality Score 
for hospitalised patients with COVID-19 in readiness to 
aid clinical management decisions in the second wave.13
We aimed to use the ISARIC CCP-UK cohort to 
describe how in-hospital mortality changed over time in 
patients admitted to hospital with COVID-19. We aimed 
to explore potential drivers for these changes by assessing 
patient characteristics, illness severity, and treatment 
received during the hospital stay.
Methods
Study design and patients
We did a multicentre prospective observational cohort 
study at 247 acute general hospitals in England, Scotland, 
and Wales. We included adults (aged ≥18 years) from the 
ISARIC WHO CCP-UK cohort admitted to hospital during 
the first wave (between March 9 and Aug 2, 2020) with 
clinical signs and symptoms of COVID-19 or confirmed 
COVID-19 (by RT-PCR test) from assumed community 
acquired infection (appendix pp 2–3). The national strategy 
changed from containment to admission based on clinical 
need on March 12, 2020.14 Further information about the 
COVID-19 care model in the first wave in UK can be found 
in the appendix (pp 1–2). Community hospitals providing 
long-term treatment and residential mental health 
hospitals were excluded since patient populations were 
very different and were therefore not comparable. We 
excluded patients with nosocomial COVID-19 infection, 
who were defined as patients with onset of COVID-19 
symptoms more than 5 days after they were admitted to 
hospital for a separate condition. 
Ethical approval for data collection and analysis by the 
ISARIC4C was given by the South Central-Oxford 
C Research Ethics Committee in England (reference 
13/SC/0149) and by the Scotland A Research Ethics 
Research in context
Evidence before this study
We searched PubMed on March 19, 2021, using the search 
terms “SARS-CoV-2” OR “COVID-19” AND “mortality” AND 
“hospital”. We searched for primary research articles 
documenting changes in COVID-19-related mortality in 
hospitals over time published between March 1, 2020, and 
March 19, 2021, with no language restrictions. Of the 
202 articles identified, most focused on risk factors for 
mortality, and we found only four studies that documented 
changes in mortality over time. None of these four studies 
explored the potential reasons for why COVID-19-related 
mortality rates in hospitals are declining beyond patient 
demographics. Understanding changes in mortality rates over 
time will help policy makers identify evolving risk and strategies 
to manage this evolving risk, and make broader decisions about 
public health interventions.
Added value of this study
To our knowledge, this is the first study to explore changes in 
COVID-19-related mortality in the context of patient 
demographics, severity of illness at presentation to hospital, 
and treatments received. Mortality in hospitalised patients at 
the beginning of the first wave (ie, between March and April, 
2020) of the pandemic was extremely high. Patients who were 
admitted to hospital in March and early April, 2020, were 
substantially more unwell at presentation than patients who 
were admitted in later months (June and July 2020). Mortality 
declined in all age groups, in all ethnic groups, in men and 
women, and in patients with and without comorbidities, over 
and above contributions from declining illness severity. 
After adjustment for these variables, a fifth of the reduction in 
mortality was explained by changes in the use of respiratory 
support and steroid treatment. However, mortality was 
persistently high in patients who required invasive mechanical 
ventilation, and in those who received non-invasive ventilation 
outside of critical care.
Implications of all the available evidence
The observed reduction in COVID-19-related hospital mortality 
was greater than would have been expected from changes 
observed in both case-mix and illness severity. This reduction in 
mortality was partly attributable to differences in respiratory 
support and critical care use, which could reflect, in part, accrual 
of clinical knowledge. In addition, the introduction of 
community policies, such as the wearing of masks, physical 
distancing, the shielding of susceptible patients, and the 
UK lockdown, potentially resulted in people being exposed to 
less virus. We found that the decrease in mortality varied 
depending on the level of respiratory support received. Patients 
receiving invasive mechanical ventilation have persistently high 
mortality rates, albeit with a changing case-mix, and further 
research should target this group of patients. Severe COVID-19 
has primarily affected older (ie, those aged >70 years) people in 
the UK. It is essential to ensure that patients and their families 
remain at the centre of decision making, and that we continue 
to use an individualised approach to their treatment and care.
For the ISARIC see 
https://isaric4c.net/
See Online for appendix
Articles
www.thelancet.com/respiratory   Published online May 14, 2021   https://doi.org/10.1016/S2213-2600(21)00175-2 3
Committee (reference 20/SS/0028). Under the Control 
of Patient Information notice 2020 for urgent public 
health research, processing of demographic and routine 
clinical data from medical records for research does not 
require patient consent in England and Wales.15 In 
Scotland, a waiver for consent was obtained from the 
Public Benefit and Privacy Panel for Health and Social 
Care. The ISARIC WHO CCP-UK study is registered 
with the ISRCTN Registry, ISRCTN66726260, and has 
been designated as an Urgent Public Health Research 
Study by the National Institute for Health Research 
(NIHR).
Procedures
Data were extracted (cutoff date Sept 17, 2020) from 
routine health-care records and recorded in case report 
forms on the REDCap database. The ISARIC 4C 
Investigators collected information on key variables 
including patient characteristics, illness severity, level of 
respiratory support, COVID-19-specific treatments, and 
in-hospital mortality. Patient characteristics included age 
group (<50 years, 50–69 years, 70–79 years, and ≥80 years, 
consistent with previous ISARIC4C studies); sex (male or 
female); self-reported ethnicity (south Asian, east Asian, 
Black, other minority ethnic group, and White);16 index of 
multiple deprivation (derived from individual patient 
postal codes); health worker status (yes or no); and 
number of comorbidities (none, one, or two or more), 
measured by use of a modified Charlson Comorbidity 
Index (see appendix [p 3] for further details).
Severity of illness at hospital admission (or within 24 h of 
admission) was assessed by use of the following 
physiological components of the ISARIC4C Mortality 
Score:13 respiratory rate (breaths per min); peripheral 
oxygen saturation on room air (SpO2); Glasgow coma scale 
score; serum urea concentration (mmol/L); and C-reactive 
protein concentration (mg/L). To capture patterns in 
access to hospital treatment, we calculated the number of 
days from symptom onset to hospital admission.
Patients were categorised as managed on the ward only 
or in critical care (ie, in the ICU or high dependency unit 
[HDU]) at any time (see appendix [pp 1–4] for more 
information on level of respiratory support). Maximum 
level of respiratory support received was classified as no 
respiratory support, oxygen (face mask, nasal cannulae, or 
high-flow nasal oxygen), non-invasive ventilation, and 
invasive mechanical ventilation.
For COVID-19-specific treatments, we only 
recorded whether patients had received corticosteroids 
(dexamethasone, hydrocortisone, methylprednisolone, 
or prednisolone), as these were the only treatments with 
recognised mortality benefit for COVID-19 in randomised 
controlled trials.9,17
The main exposure of interest was the week of admission 
to hospital, defined as the International Organization for 
Standardization date week (ie, the ordinal week of the 
year). To facilitate comparison across time periods, week of 
admission to hospital was also categorised into three equal 
time periods (time period 1 included weeks 11–17 [ from 
March 9 to April 26, 2020]; time period 2 included 
weeks 18–24 [ from April 27 to June 14, 2020]; and time 
period 3 included weeks 25–31 [ from June 15 to 
Aug 2, 2020]).
Outcomes
The primary outcome was the weekly in-hospital 
mortality at 28 days, defined as the proportion of patients 
who had died within 28 days of admission of all patients 
admitted in the observed week. Mortality was defined as 
an outcome of death or discharge to palliative care. The 
28-day threshold aligns with the Public Health England 
definition of death due to COVID-19.18 We included all 
patients who were admitted to hospital at least 6 weeks 
before data analysis to allow for 28 days follow-up.
Secondary outcomes were changes in patient demo-
graphics and illness severity in patients managed on the 
ward and in critical care units. Within critical care, we 
looked separately at changes in the proportion of patients 
receiving oxygen only, non-invasive ventilation, and 
invasive mechanical ventilation. Within ward care, we 
looked at changes in the proportion of patients receiving 
no respiratory support, oxygen only, and non-invasive 
ventilation. We performed two sensitivity analyses: a 
complete case analysis in which only patients with 
outcomes (survived, died, or ongoing care) were included 
and an analysis in which patients with missing outcomes 
were assumed to be survivors.
Statistical analysis
Continuous data are presented as means (SDs) or medians 
(IQRs) depending on the distribution. Categorical data are 
presented as percentage frequencies. For univariable 
comparisons, we used Welch’s t test, ANOVA, Mann-
Whitney U test, or Kruskal-Wallis tests, according to data 
distribution. Categorical data were compared by use of 
χ² tests. Counts and proportions for each of the exposure 
variables were calculated across the three time periods. 
The proportion of patients admitted each week and weekly 
in-hospital mortality at 28 days were stratified by each 
explanatory variable of interest. 95% CIs for these 
proportions were calculated by use of the exact method.
There were missing data because of the challenges of 
real-time data collection during a pandemic. Missing data 
are reported in the results section and in appendix  (pp 
37–39), and patterns of missing data were explored. 
Missing data for number of comorbidities were classified 
as none, for health-care worker status were classified as 
no, and for respiratory support received (ie, oxygen, 
invasive mechanical ventilation, and non-invasive 
ventilation) were classified as none. For the primary 
analysis, multiple imputation with chained equations was 
done for missing markers of illness severity. Ten sets, 
each with ten iterations, were imputed by use of 
35 explanatory variables including outcomes. We did 
For the Public Benefit and 
Privacy Panel for Health and 
Social Care see https://www.
informationgovernance.scot.
nhs.uk/pbpphsc/
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graphical checks of convergence. All analyses were done 
by use of imputed datasets (see appendix [p 3] for further 
details).
For the primary outcome analysis, we excluded 
patients without an outcome date (classified as 
“survivors” in the sensitivity analysis results in the 
appendix [p 31). For the primary outcome, our 
modelling strategy was informed by a putative causal 
model (see the proposed directed acyclic graph in the 
appendix [p 26]). Using logistic regression, we specified 
three models exploring the association between 
admission week (as a continuous variable) and 
in-hospital mortality. A baseline model included 
adjustment for age, sex, and admitting hospital as a 
random effect. A second model accounted for known 
baseline confounders, including variables previously 
shown to be associated with in-hospital mortality (age, 
sex, number of comorbidities, index of multiple 
deprivation score, and severity of illness [respiratory 
rate, SpO2, Glasgow coma scale score, serum urea 
concentration, and C-reactive protein concentration]). 
In a third model, potential mediators were added to 
explore the effect of treatment (steroids and respiratory 
support, thus considering accrued clinical knowledge 
of respiratory support) on the association between week 
of admission and mortality (controlled direct-effect 
models). We extended this same model in a potential 
outcomes framework to perform a three-way 
decomposition mediation analysis using natural effects 
models.19 We sought to control confounding between 
exposure and outcome, exposure and mediator, and 
mediator and outcome, and we carefully considered 
potential mediator-outcome confounders influenced by 
the exposure. Using standard frequentist approaches, 
we imputed unobserved nested counterfactuals with an 
outcome model to accommodate our nominal mediator 
(respiratory support). Exposure-mediator interactions 
were explored and a joint model was used to incorporate 
steroid use. Robust SEs (based on a Sandwich estimator) 
were generated, and the results were presented as a 
proportion mediated on the risk difference scale.
For the secondary outcomes, to better understand 
patterns of mortality for different levels of respiratory 
support, time-series data were modelled with 
Bayesian generalised additive models to allow for easy 
incorporation of multiply imputed datasets (see 
appendix [p 3] for more details).
All statistical analyses were done in R (version 3.6.3) 
and Stan (rstan 2.21.2 and brms 2.14.4) with the tidyverse, 
finalfit, brms, mgcv, mice, medflex, gridExtra and 
cowplot packages. This study is registered with the 
ISRCTN Registry, ISRCTN66726260.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Between March 9, and Aug 2, 2020, we recruited 
80 713 patients from 247 acute hospitals in England, 
Scotland, and Wales, of whom 63 972 were eligible and 
included in the final cohort (table; appendix pp 5–7), 
representing approximately 48% of all hospital 
admissions in the UK during this time period.1 
Admissions peaked in late March and in early April for 
all age groups, and steadily decreased until the end of the 
study period (figure 1A). A total of 15 864 (29·0%) of 
54 632 patients managed on wards died within 28 days of 
hospital admission compared with 3317 (35·5%) of 
9340 patients in critical care (appendix p 24). Of all 
63 972 patients, 40 449 (63·2%) had a documented 
positive COVID-19 RT-PCR test result (appendix pp 6–7).
Most patients (55 562 [86·9%] of 63 972) admitted 
during the first wave were aged 50 years or older. There 
was an increase in the proportion of younger people 
(ie, those aged <50 years) admitted over time 
(6261 [13·2%] of 47 453 patients in time period 1 vs 
486 [17·5%] of 2775 patients in time period 3; table, 
figure 2A). There were initially more men admitted than 
women (27 616 [58·2%] of 47 453 patients in time 
period 1 were men), but the proportions of men and 
women were similar from mid-April to Aug 2, 2020 
(figure 2B). The cohort was multimorbid, with 
25 275 (53·3%) of 47 453 patients in time period 1 having 
two or more comorbidities. The proportion of patients 
with two or more comorbidities increased over time 
(table, figure 2C; appendix p 7). Most patients were 
White, with an increasing proportion of south Asian 
patients and a decreasing proportion of patients from 
Black ethnic groups over time (figure 2D). In all time 
periods, the highest proportion of patients were in the 
most deprived quintile, and the proportion of patients in 
this deprivation quintile increased over time (figure 2E).
Illness severity peaked from around March 30 to 
April 12, 2020 (weeks 14–16), when patients had faster 
respiratory rates, lower peripheral oxygen saturations on 
room air, and lower Glasgow coma scores, higher levels 
of acute kidney injury, and higher levels of inflammation 
at presentation to hospital than did patients admitted 
subsequently (figure 3). Patients presented later in their 
disease course at the beginning of the first wave 
compared with at the end of the first wave (median 4 days 
(IQR 0–7) in time period 1 vs 2 days (0–7) in time period 2 
vs 3 days (0–7) in time period 3; table).
At the peak of admissions in time period 1, 38 139 
(80·4%) patients admitted to hospital received 
supplementary oxygen. The proportion of patients 
receiving supplementary oxygen reduced consistently over 
subsequent weeks to approxi mately 50% in patients 
admitted from July onwards (table).
Most patients (54 632 [85·4%) of 63 972) admitted 
during the first wave were managed on the ward, with 
the proportion of patients admitted to critical care units 
peaking at the start of the first wave (7732 [16·3%] of 
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47 453 patients in time period 1; table; appendix pp 8,28). 
Compared with patients on wards, those in critical care 
units were younger (appendix pp 8–9) and more likely to 
be male (6433 [68·9%] of 9340 in critical care units vs 
29 690 [54·3%] of 54  632 on wards; appendix pp 8–11). 
Patients with multiple comorbidities accounted for a 
substantial proportion of the total number of patients 
admitted (3733 [40·0%] of 9340 patients admitted to 
critical care units had two or more comorbidities vs 
32 531 [59·5%] of 54 632 patients admitted to wards had 
two or more comorbidities; appendix pp 8–11). In critical 
care units, the proportions of younger patients and those 
Time period 1; 
weeks 11–17 
(n=47 453)
Time period 2; 
weeks 18–24 
(n=13 744)





England 43 326 (91·3%) 12 579 (91·5%) 2589 (93·3%)
Scotland 2140 (4·5%) 534 (3·9%) 33 (1·2%)








Mean 70·1 (16·7) 72·6 (17·3) 69 (18·6)
Age group, years
<50 6261 (13·2%) 1663 (12·1%) 486 (17·5%)
50–69 14 284 (30·1%) 3261 (23·7%) 734 (26·5%)
70–79 10 675 (22·5%) 3015 (21·9%) 590 (21·3%)
≥80 16 233 (34·2%) 5805 (42·2%) 965 (34·8%)
Sex
Female 19 837 (41·8%) 6659 (48·5%) 1353 (48·8%)
Male 27 616 (58·2%) 7085 (51·5%) 1422 (51·2%)
Ethnicity
White 33 993 (71·6%) 10 832 (78·8%) 1922 (69·3%)
South Asian 2279 (4·8%) 530 (3·9%) 296 (10·7%)
East Asian 398 (0·8%) 41 (0·3%) 12 (0·4%)
Black 2015 (4·2%) 236 (1·7%) 41 (1·5%)
Other minority 
ethnic group
3340 (7%) 681 (5%) 229 (8·3%)
Missing data 5428 (11·4%) 1424 (10·4%) 275 (9·9%)
Number of comorbidities
0 10 789 (22·7%) 2014 (14·7%) 507 (18·3%)
1 11 389 (24·0%) 2463 (17·9%) 546 (19·7%)
≥2 25 275 (53·3%) 9267 (67·4%) 1722 (62·1%)
Health worker 2419 (5·1%) 738 (5·4%) 77 (2·8%)
Severity of illness








Mean 5·0 (5·2) 4·1 (5·2) 4·1 (4·9)







Mean 11·0 (12·6) 12·2 (11·9) 10·6 (9·7)
ISARIC4C mortality score
Low (0–3) 2056 (4·3%) 726 (5·3%) 196 (7·1%)
Intermediate (4–8) 7469 (15·7%) 2020 (14·7%) 506 (18·2%)
High (9–14) 16 509 (34·8%) 5416 (39·4%) 1042 (37·5%)
Very high (≥15) 5055 (10·7%) 1321 (9·6%) 156 (5·6%)
Missing data 16 364 (34·5%) 4261 (31%) 875 (31·5%)
Respiratory rate, breaths per min
<20 13 066 (27·5%) 5303 (38·6%) 1131 (40·8%)
20–30 23 791 (50·1%) 6232 (45·3%) 1197 (43·1%)
≥30 8433 (17·8%) 1670 (12·2%) 305 (11%)
Missing data 2163 (4·6%) 539 (3·9%) 142 (5·1%)
(Table continues in next column)
Time period 1; 
weeks 11–17 
(n=47 453)
Time period 2; 
weeks 18–24 
(n=13 744)
Time period 3; 
weeks 25–31 
(n=2775)
(Continued from previous column)
Peripheral oxygen saturation on room air
≥92% 34 345 (72·4%) 10 970 (79·8%) 2259 (81·4%)
<92% 10 667 (22·5%) 2224 (16·2%) 378 (13·6%)
Missing data 2441 (5·1%) 550 (4%) 138 (5%)
Glasgow coma scale score
15 35 403 (74·6%) 10 857 (79%) 2323 (83·7%)
<15 6645 (14%) 1911 (13·9%) 250 (9%)
Missing data 5405 (11·4%) 976 (7·1%) 202 (7·3%)
Urea, mmol/L
<7 17 581 (37%) 5250 (38·2%) 1195 (43·1%)
7–14 12 785 (26·9%) 3858 (28·1%) 757 (27·3%)
>14 6572 (13·8%) 1869 (13·6%) 286 (10·3%)
Missing data 10 515 (22·2%) 2767 (20·1%) 537 (19·4%)
C-reactive protein, mg/dL
<50 11 714 (24·7%) 4775 (34·7%) 1037 (37·4%)
50–99 9400 (19·8%) 2397 (17·4%) 442 (15·9%)
≥100 17 948 (37·8%) 3736 (27·2%) 684 (24·6%)
Missing data 8391 (17·7%) 2836 (20·6%) 612 (22·1%)
Respiratory support and treatments
Threshold of care
Critical care unit 7732 (16·3%) 1275 (9·3%) 333 (12%)
Ward 39 721 (83·7%) 12 469 (90·7%) 2442 (88%)
Respiratory support
None 9314 (19·6%) 4780 (34·8%) 1184 (42·7%)
Oxygen only 28 023 (59·1%) 7170 (52·2%) 1221 (44%)
Non-invasive 5158 (10·9%) 1240 (9%) 272 (9·8%)
Invasive 4958 (10·4%) 554 (4%) 98 (3·5%)
Steroids
Yes 7354 (15·5%) 2267 (16·5%) 910 (32·8%)
No 37 162 (78·3%) 10 875 (79·1%) 1731 (62·4%)
Missing data 2937 (6·2%) 602 (4·4%) 134 (4·8%)
Data are n (%), median (IQR), or mean (SD). Time period 1 was from March 9 to 
April 26, 2020; time period 2 was from April 27 to June 14, 2020; and time 
period 3 was from June 15 to Aug 2, 2020. *Symptom onset summary statistics 
based on patients with symptoms up to 3 weeks before admission only. 
ISARIC4C=International Severe Acute Respiratory and Emerging Infections 
Consortium Coronavirus Clinical Characterisation Consortium.
Table: Baseline characteristics of adult patients admitted to hospital 
with COVID-19, stratified by time (N=63 972) 
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with multiple comorbidities increased over time; a 
pattern that was also observed in patients admitted to 
wards (appendix pp 8–11).
The level of respiratory support received reduced over 
time in patients admitted to critical care units and wards 
(appendix pp 8–11). In critical care units, the requirement 
for invasive mechanical ventilation declined over time 
(4958 [64·1%] of 7732 patients in time period 1 vs 98 [29·4%] 
of 333 patients in time period 3), the proportion of patients 
requiring non-invasive ventilation increased substantially 
from 1768 (22·9%) patients in time period 1 to 
157 (47·1%) patients in time period 3 (appendix pp 8–9). 
By comparison, the proportion of patients admitted to 
wards on non-invasive ventilation remained low, 
decreasing from 3390 (8·5%) of 39 721 patients in time 
period 1 to 115 (4·7%) of 2442 patients in time period 3 
(appendix pp 10–11). By the end of the first wave, 
42·7% of patients (1184 of 2775) admitted to hospital 
received no respiratory support (1184 [48·5%] of 
2442 patients admitted to wards received no respiratory 
support; table; appendix pp 10–11). More information on 
the characteristics of patients admitted to critical care 
units and wards, and the proportions of patients receiving 
respiratory support are included in the appendix (pp 8–23).
The proportion of patients who received steroids 
increased from 7354 (15·5%) of 47 453 patients 
(2069 [26·8%] of 7732 patients in critical care units) in 
time period 1 to 910 (32·8%) of 2775 patients (223 [67·0%] 
of 333 patients in critical care units) in time period 3, 
mainly in patients receiving respiratory support (table; 
appendix pp 8–23, 29).
Unadjusted weekly in-hospital mortality at 28 days 
declined from 32·3% (95% CI 31·8–32·7) in the period 
from March 9 to April 26, 2020, to 16·4% (15·0–17·8) in 
Figure 1: Hospital admissions and in-hospital mortality between March 9 and Aug 2, 2020
(A) Daily adult COVID-19 admissions by age. Cases are stacked by age group. (B) Weekly unadjusted mortality in adult inpatients admitted to hospital with COVID-19. 
Error bars represent 95% CIs, calculated by use of an exact method. Dashed lines indicate three equal time periods (weeks 11–17, 18–24, and 25–31).
Weeks 11−17;
March 9 to April 26, 2020
Weeks 18−24;
April 27 to June 14, 2020
Weeks 25−31;
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the period from June 15 to August 2, 2020 (figure 1B; 
appendix p 24). This reduction in weekly in-hospital 
mortality at 28 days did not differ substantially in the 
sensitivity analyses, in which patients without an 
outcome were reclassified as survivors (appendix p 31), 
nor when patients who died in hospital more than 
28 days after admission were included (a further 5% of 
patients died after 28 days; see appendix p 32 for 
subgroup analysis).
In-hospital mortality was higher with increasing age, 
increasing number of comorbidities, and male sex 
(figure 2). Over the course of the first wave, in-hospital 
mortality declined for all demographic categories, most 
notably in older patients (7867 [48·5%] of 16 233 patients 
aged ≥80 years died in time period 1 vs 239 [24·8%] of 
965 patients aged ≥80 years in time period 3) and 
comorbid populations (figure 2; appendix p 7). Markers of 
increased severity of illness at presentation to hospital 
were associated with increased in-hospital mortality. In-
hospital mortality declined for all markers of severity of 
illness over time (figure 3) and for patients treated on 
wards and in critical care units (appendix pp 24, 28, 29).
There was a 35% reduction in the odds of in-hospital 
mortality per 7-week time period (odds ratio [OR] 0·65 
[95% CI 0·63–0·67], p<0·0001; figure 4). After adjustment 
for age, sex, deprivation, and hospital, the odds of 
in-hospital mortality per 7-week time period was 0·58 
(0·56–0·60; p<0·0001). After additional adjustment for 
illness severity and number of comorbidities, the effect of 
week of admission on in-hospital mortality was similar to 
the effect before we adjusted for illness severity and 
comorbidity count (OR 0·61 [0·58–0·64], p<0·0001). With 
the addition of the mediator variables (respiratory support 
or steroid treatment), the OR reduced to 0·68 (0·65–0·71; 
p<0·0001). Case mix and illness severity accounted for 
10·2% of the reduction in mortality, and 22·2% (OR 0·95 
[0·94–0·95], p<0·0001) of the effect of week of admission 
on in-hospital mortality was mediated through respiratory 
care and steroid treatment (figure 5). There was a 
significant interaction between respiratory support and 
week of admission (p<0·0001).
There were substantial reductions in unadjusted 
in-hospital mortality between time period 1 and time 
period 3 in patients receiving no respiratory support 
(1339 [14·0%] of 9564 patients in time period 1 vs 71 [6·0%] 
Figure 2: Proportion of adults admitted to hospital with COVID-19 and 
inpatient mortality between March 9 and Aug 2, 2020, stratified by age (A), 
sex at birth (B), number of comorbidities (C), ethnic group (D), and 
deprivation quintile (E)
In A–E, all plots on the left show the proportion of adults admitted to hospital 
with COVID-19 by patient characteristics, and all plots on the right show 
unadjusted in-hospital mortality rates during the time period. In all plots on the 
left, the proportions of participants are stacked by characteristic. In E, the 
deprivation quintile ranges from 1 (most deprived) to 5 (least deprived). Missing 

















































































































































































































<50 years 50–69 years 70–79 years ≥80 years
Sex Male Female
B   Sex at birth
Number of comorbidities
C   Number of comorbidities
0 1 ≥2
Ethnic group
D   Ethnic group
White South Asian East Asian Black Other minority ethnic group
Deprivation quintile
E   Deprivation quintile
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of 1183 patients in time period 3), oxygen only 
(9496 [35·1%] of 27 054  patients admitted to wards in 
time period 1 vs 243 [21·3%] of 1141 patients admitted to 
wards in time period 3; and 228 [22·7%] of 1004 patients 
admitted to critical care units in time period 1 vs 
ten [12·8%] of 78 patients admitted to critical care units in 
time period 3), and non-invasive ventilation in critical 
care units (587 [33·2%] of 1768 patients in time period 1 vs 
39 [24·8%] of 157 patients in time period 3) across all age 
groups (appendix pp 8–23). However, in-hospital mortality 
remained persistently high for patients receiving invasive 
mechanical ventilation (2034 [41·0%] of 4961 patients in 
time period 1 vs  41 [41·8%] of 98 patients in time period 3) 
and non-invasive ventilation on the ward (1626 [48·0%] of 
3387 patients vs 51 [44·3%] of 115 patients). These 
differential changes in in-hospital mortality persisted 
after adjustment for demographic and severity of illness 
variables (appendix p 30).
Discussion
Overall in-hospital mortality within 28 days of admission 
substantially decreased during the first wave of the 
pandemic in the UK. At the peak of admissions in 
late March and early April, 2020, patients were sub-
stantially more unwell at presentation to hospital and 
presented later from their onset of symptoms than those 
presenting to hospital at later months. There was a 
reduction in the level of respiratory support received; use 
of invasive ventilation reduced over time, and the 
proportion of patients receiving non-invasive ventilation 
increased. By late June and early August, almost half of 
patients admitted required no supplementary oxygen. 
The reduction in in-hospital mortality during the first 
wave was observed across all demographic groups, and 
was not fully accounted for by changes in the case-mix or 
a reduction in illness severity at hospital admission. 
One-fifth of the reduction in in-hospital mortality could 
be accounted for by changes in treatment, including 
respiratory care and steroid treatment.
ISARIC4C has recruited patients from hospitals 
across the UK, accounting for approximately two-thirds 
of patients admitted to hospital in the UK with 
COVID-19 in the first wave. Data were collected from 
arrival in the Emergency Department to discharge for 
patients managed both on wards and in critical care 



















































































































































































































A   Respiratory rate
<20 breaths per min 20–30 breaths per min ≥30 breaths per min
Oxygen saturation ≥92% <92%
B   Peripheral oxygen saturation on room air
Glasgow coma score
C   Glasgow coma score
15 <15
Urea
D   Urea
<7 mmol/L 7–14 mmol/L >14 mmol/L
C−reactive protein
E   C−reactive protein
<50 mg/L 50–99 mg/L ≥100 mg/L
Figure 3: Proportion of adults admitted to hospital with COVID-19 and 
inpatient mortality between March 9 and Aug 2, 2020, stratified by 
respiratory rate (A), peripheral oxygen saturation on room air (B), Glasgow 
coma score (C), urea concentration (D), and C-reactive protein 
concentration (E) 
In A–E, all plots on the left show the proportion of adults admitted to hospital 
with COVID-19 by severity of illness at admission, and all plots on the right show 
the unadjusted in-hospital mortality rate each week during the time period. In 
all plots on the left, the proportions of participants are stacked by severity of 
illness at admission. Missing data are excluded from the figure. 
Articles
www.thelancet.com/respiratory   Published online May 14, 2021   https://doi.org/10.1016/S2213-2600(21)00175-2 9
rates in whole hospitals rather than just in critical care 
units.
We showed a reduction in in-hospital mortality during 
the first wave that cannot be fully explained by baseline 
patient demographics or measured presenting severity of 
illness markers. These trends are consistent with those 
observed in New York hospitals,20 where mortality also 
significantly and progressively declined between March 
and August, 2020. Mortality rates in critical care units in 
the UK have also reduced over this time.21,22 Most patients 
admitted to hospital during the first wave were older 
(ie, median age 70 years), had two or more comorbidities, 
and were of White ethnicity, and in-hospital mortality was 
highest in these groups. The case-mix has changed over 
the course of the pandemic, with an increase in the 
proportion of patients younger than 50 years and female 
patients who, both in our study and in other studies, have 
lower mortality rates than older groups and male 
patients.23,24 However the declines in mortality were 
observed in all age groups, ethnic groups, and in both 
sexes. Shielding of susceptible groups was formally 
introduced in the UK on March 23, 2020,25 and patients 













































































p valueA   Week of admission alone
B   Baseline adjustment
C   Total effect
D   Controlled direct effect
1 2 5 10 15
Figure 4: OR for in-hospital mortality for week of admission per 7-week period
In-hospital mortality unadjusted for week of admission (A); adjusted for age, sex, deprivation, and hospital (B); adjusted for age, sex, deprivation quintile, severity of 
illness (respiratory rate, oxygen saturations, Glasgow coma score, serum urea concentration, and C-reactive protein), and number of comorbidities (C); and adjusted 
for age, sex, deprivation quintile, severity of illness, number of comorbidities, and potential mediators (maximal level of care, respiratory support, and treatment with 
steroids). Error bars represent 95% CIs. OR=odds ratio. 
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presenting before shielding was introduced might have 
been more susceptible but not identifiable in our dataset. 
Severity of illness at presentation to hospital decreased, 
and the proportion of patients requiring no respiratory 
support increased at the end compared with at the start of 
the first wave. SARS-CoV-2 is transmitted predominantly 
by respira tory droplets; therefore, physical distancing, 
lockdown (between March 23, 2020, and July 4, 2020),26 
and widespread adoption of face masks could have 
reduced viral load (ie, the infectious dose) at the point of 
transmission,27 thus reducing severity of illness in infected 
patients.28 Compared with March and April, 2020, patients 
presented earlier in the disease course in June and 
July, 2020, and length of stay of non-survivors in critical 
care units increased, consistent with patients presenting 
earlier in their illness and fewer in extremis. Our data do 
not include community factors; however, it is possible that 
changes in health-seeking behaviour might have led to 
patients attending hospitals more easily and earlier.
Hospital admissions in the UK peaked at approximately 
3000 patients admitted per day in early April, 2020, with 
the ICU caseload peaking shortly after this point1,2 before 
gradually declining to a plateau of approximately 
100 patients admitted per day by July, 2020.1 The UK has 
a small health-care workforce, with few hospital and 
critical care beds per capita relative to other high income 
countries.29,30 At the start of the pandemic, the UK had 
high occupancy of hospital beds and little spare capacity.29 
However, during the rapid response to COVID-19, an 
additional 2711 beds compatible with mechanical 
ventilation across England were made available, 
reflecting a 53% increase in capacity.31 National reported 
occupancy in critical care units never exceeded 62%, 
although local peaks in critical care unit occupancy were 
much higher than this value, with 52 hospitals across 
England reaching 100% occupancy at one or more points 
during the first wave of the pandemic.30,31 The effect of 
increased patient numbers could have been different 
depending on the type and size of the hospital, with 
smaller hospitals reaching full capacity sooner than 
larger hospitals. Even before the pandemic, critical care 







































Figure 5: Causal graph with natural effects models mediation analysis
The OR for the total natural indirect effect was 0·95 (95% CI 0·94–0·95, p<0·0001; percentage of effect through indirect path 22·2%; joint mediators) and for the pure 
natural direct effect was 0·84 (0·82–0·87, p<0·0001; percentage of effect from direct path 77·8%). IMD=index of multiple deprivation. YXM and YM=unmeasured 
confounders. OR=odds ratio. *Arrows from steroid treatment mediator confounders are not shown for clarity.
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The rapid increase in critical care beds required 
redeployment of non-critical care staff, and in some UK 
regions, increased nursing staff-to-patient ratios, which 
could have influenced early patient outcomes.33
In the first time period late March, early April, we found 
that a higher proportion of patients were admitted to 
critical care units than later. Patients in critical care units 
at this time were considerably younger than those on 
wards; even so, in-hospital mortality was much higher for 
COVID-19 than for other severe acute respiratory 
infections, such as viral pneumonia.7 During the peak 
admission period, the proportion of patients aged older 
than 80 years and the proportion of patients with two or 
more comorbidities admitted to critical care units was 
lower than after this time point; however, this pattern 
reflected the demographic of patients admitted to wards 
during the peak admission period.
 A fifth of the reduction in in-hospital mortality in our 
study can be explained by changes in respiratory support 
and steroid treatment, together with associated changes in 
clinical decision making associated with respiratory 
support. At the beginning of the pandemic, much 
attention was given to early intubation and to different 
ventilator management practices based on different 
presumed phenotypes. These practices changed as 
clinicians started to manage acute respiratory distress 
syndrome (ARDS) from COVID-19 as routine ARDS. The 
proportion of patients receiving invasive ventilation 
reduced over time; however, in-mortality remained 
persistently high after adjusting for patient demographics 
and illness severity, as shown in our study. It would be 
unwise to interpret this association as causal, as use of 
invasive mechanical ventilation is reserved for patients 
with the most severe illness, and there was an overall 
reduction in mortality in patients with COVID-19 admitted 
to critical care units in our study. There are several 
potential explanations for this finding. First, the change in 
case-mix might not have been adequately captured by 
multimorbidity and age; a higher proportion of older 
patients (ie, those older than 70 years) and patients with 
comorbidities were ventilated later in the first wave, 
potentially at a time when there was more critical care 
capacity than at the start of the first wave. Second, critical 
care practices changed, with increasing use of non-invasive 
ventilation over time, and only patients presenting in 
extremis or those who did not respond to a trial of 
non-invasive ventilation received invasive mechanical 
ventilation. This change in practice could be partly due to 
the changing case-mix, but also due to increasing clinician 
familiarity with the use of non-invasive ventilation, and an 
improving ability to identify which patients might benefit 
from this intervention.34 It is possible that patients 
admitted early in the first wave who received invasive 
mechanical ventilation would have received non-invasive 
ventilation if they had been admitted later in the first 
wave, and that they would have survived regardless of the 
mode of ventilation. Therefore, compared with patients 
who received invasive mechanical ventilation early in the 
first wave, those admitted later who received invasive 
mechanical ventilation were a more severely ill population 
who had failed to respond to treatments and would die if 
not offered invasive mechanical ventilation. This notion is 
supported by the significant increase in the effect of 
respiratory care over time; allocation to respiratory support 
was linked to better prediction of outcome by clinicians 
over time in our study. Ongoing trials comparing the use 
of non-invasive ventilation and invasive mechanical 
ventilation in critically ill patients with COVID-19 will 
help to overcome this selection bias and confounding by 
indication to ascertain whether patient selection or 
non-invasive ventilation itself is improving outcomes in 
critically ill patients with COVID-19.
In our study, in-hospital mortality rates in patients 
receiving non-invasive ventilation on the ward were 
higher than in patients receiving oxygen and non-invasive 
ventilation being managed in critical care units. Together 
with a higher proportion of patients with comorbidities, 
particularly dementia and chronic pulmonary and 
cardiac disease, this observation could indicate that the 
benefit of these treatments in this group of patients is 
limited, and could also indicate a potential ceiling of 
treatment for patients receiving non-invasive ventilation 
on the ward. In-hospital mortality was high in older 
patients (ie, those older than 80 years) who received 
invasive ventilation. The benefit of ICU admission for 
older frail patients remains uncertain, as rates of 
mortality and long-term functional impairment in 
survivors are high in this population.35 Critical care 
interventions might not be associated with improved 
outcomes in this group. In a previous study, protocolised 
ICU referral in patients aged 75 years and older led to 
significantly higher ICU admission rates but had no 
significant effect on mortality, functional status, or 
health-related quality of life.36 It is essential that 
meaningful discussions about the available treatment 
options, as well as the risks and benefits of each, are 
discussed with these patients and their families.37 Such 
discussions should also emphasise that much of the 
potential benefit of care can be derived without the need 
for ICU level care.
Clinical practice outside critical care has also changed 
during the first wave, with increasing clinical familiarity 
with COVID-19. Clinicians might have become more alert 
to deterioration, which can occur rapidly during COVID-19 
infection, and might not have been accurately captured by 
our data collection. Corticosteroid treatment9,10 
substantially benefits sub groups of hospital inpatients, 
and trials of other treatments, including anticoagulants, 
anti-inflammatory drugs, anti-viral drugs, convalescent 
plasma, and non-invasive ventilation are ongoing.9,10 These 
evidence-based COVID-19 interventions highlight the 
critical importance of suitably powered randomised 
controlled trials for drug evaluation, even in outbreak 
situations.
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This observational cohort study has some limitations. 
We did not record treatment escalation plans, but we 
were able to examine changing case-mixes in the ward 
and in critical care units. Due to the nature of the 
pandemic, there were more missing data than would 
normally be expected in a prospective cohort study, but 
missing data were handled with the appropriate methods, 
as discussed in the methods and appendix. We were 
unable to comment on community factors leading up to 
admission, and indeed, for patients who were not 
admitted to hospital. The change in management of 
ventilated patients would have benefitted from 
measurement of physiological variables; however, we did 
not collect this information. We also did not include 
unproven treatments being investigated in randomised 
controlled trials, which could have had either a beneficial 
or harmful effect. We were unable to locate any publicly 
available data for strain in the National Health Service 
(NHS) during the first wave (ie, excessive demand on the 
strength, resources, or abilities of hospitals). Although 
data on the proportion of ICUs that had reached so-called 
surge capacity were available for Scotland, equivalent 
data for England were not available. Furthermore, 
different hospitals had surges in both daily admissions 
and number of in-patients at different times; therefore, 
defining a time when hospitals were working beyond 
their pre-COVID-19 capacity was complex. We were 
unable to identify individual hospital strain; however, we 
did include hospital as a variable in our model. We used 
components of the ISARIC4C Mortality Score for severity 
of illness at presentation. This is a pragmatic score-based 
model, therefore discrimination and calibration might be 
reduced in subgroups of patients. Furthermore, with 
changes in treatment and outcomes over time, predicted 
in-mortality could be overestimated. However, in internal 
temporal and external validation studies, performance of 
this model has remained good. As this was an 
observational study, we were unable to assign causality, 
and unmeasured confounding might remain. The issue 
of selection bias for those admitted to critical care, 
compared with those who are cared for on the ward (ie, 
collider bias), is well established in critical care 
epidemiology literature, and its effect on associations is 
understood. The comparison of ward versus critical care 
cohorts is absent from most other studies.
In conclusion, in-hospital mortality rates in patients 
with COVID-19 declined in the UK during the first wave 
of the pandemic. This reduction persisted after adjusting 
for illness severity and changes in patient case-mix. 
Patients were most severely unwell at hospital presen-
tation at the start of the first wave and presented later in 
the disease course than did patients at the end of the first 
wave. A significant proportion of the reduction in 
in-hospital mortality can be explained by changes in 
clinical management, including respiratory support and 
steroid treatment. Hospital practice has changed; the use 
of non-invasive ventilation has increased substantially, 
and many patients have been included in drug trials and 
trials of other treatments, which might explain the 
reduction in in-hospital mortality and inform future 
waves. In-hospital mortality remained high for patients 
receiving invasive ventilation and non-invasive ventilation 
on the ward, and these populations should be a priority in 
ongoing research.
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